22.2 C
New York
Friday, July 4, 2025

Tag: partnership

Shah Rukh Khan to Grace the Grand Opening of City of Dreams Sri Lanka

MUMBAI, India, July 4, 2025 /PRNewswire/ -- The undisputed King of Bollywood, Shah Rukh Khan, is set to make a spectacular visit to Sri Lanka,...

PETRO-VICTORY ENERGY CORP. AND AZEVEDO & TRAVASSOS ENERGIA S.A. SIGN BINDING MEMORANDUM OF UNDERSTANDING

DALLAS, July 4, 2025 /CNW/ - Petro-Victory Energy Corp. (TSXV: VRY) ("Petro-Victory" or the "Company") and Azevedo & Travassos Energia S.A. ("ATE") are pleased to...

MR.DIY Announces Rajkummar Rao as the Brand Ambassador with their ‘Milega kya, Mat Pooch – MR.DIY has Sabkuch’ campaign

Campaign film link: MUMBAI, India, July 4, 2025 /PRNewswire/ -- MR.DIY, Asia's largest home improvement and lifestyle retail chain, is delighted to announce the...

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions

Yingfa Ruineng Joins UN Global Compact, Aiming to Lead Photovoltaic Sector Through Sustainability

YIBIN, China, July 4, 2025 /PRNewswire/ -- Sichuan Yingfa Ruineng Technology Co., Ltd. ("Yingfa Ruineng") has recently announced its formal accession to the United Nations...

SOILBUILD INTERNATIONAL BREAKS NEW GROUND IN VIETNAM WITH SPECTRUM HƯNG YÊN INDUSTRIAL LAUNCH IN 2025

HANOI, Vietnam, July 4, 2025 /PRNewswire/ -- Soilbuild International has officially broken ground on Spectrum Hung Yen, a cutting-edge industrial development spanning over 14.45 hectares in...

Military Veterans Can Win Free Travel Franchise From Dream Vacations

Dream Vacations travel agency franchise launches 14th annual "Operation Vetrepreneur: Become Your Own General" contest® FORT LAUDERDALE, Fla., July 4, 2025 /PRNewswire/ -- Leading travel agency...

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist

Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist, following the recent clearance of an Investigational New Drug (IND) application by the US Food and Drug Administration (FDA) for a Phase 1 clinical study of ORX142 in healthy volunteers. (click here).

FinSei Ltd Partners with FinHub.cloud to Accelerate Next-Generation Payment Solutions Across the UK and Europe

LONDON, July 4, 2025 /PRNewswire/ -- FinSei (previously AltPay.uk), an innovative fintech company specializing in secure, seamless payment services, has announced a strategic partnership with...

FinSei Ltd Partners with FinHub.cloud to Accelerate Next-Generation Payment Solutions Across the UK and Europe

LONDON, July 4, 2025 /PRNewswire/ -- FinSei (previously AltPay.uk), an innovative fintech company specializing in secure, seamless payment services, has announced a strategic partnership with...

Smartee Chief Scientist Appointed Full Professor at Italy’s Historic University of Padua

Smartee Denti-Technology Forms Landmark Academic Partnership with 800-Year-Old European Institution ROME, July 4, 2025 /PRNewswire/ -- The University of Padua, Italy's second-oldest and one...

AsiaPay Partners with Tai Wo Management to Launch JOIE digital Payment Solution, Enhancing the Taxi Experience in Hong Kong

HONG KONG, July 4, 2025 /PRNewswire/ -- AsiaPay, a prominent provider of digital payment solutions in the Asia-Pacific region, announced today a partnership with...

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPartnership